| CEO Name | Emma Walmsley |
| Nationality | United Kingdom |
| Net Worth Estimation | $40 million |
Emma Walmsley, CEO of GlaxoSmithKline plc, has an estimated net worth of around $40 million, primarily derived from her executive salary, performance bonuses, stock options, and long-term incentives awarded during her tenure. Her compensation reflects her leadership at GSK and her previous executive roles at L'Oreal.
Emma Walmsley, CEO of GlaxoSmithKline plc, has an estimated net worth of $40,000,000, which is 8% of the maximum estimated net worth ($500,000,000) and 400% of the minimum ($10,000,000) for pharmaceutical CEOs. This places her net worth towards the lower-middle range compared to peers in the industry.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Emma Walmsley Performance in GlaxoSmithKline plc
Emma Walmsley, CEO of GlaxoSmithKline plc, demonstrates transformative leadership through strategic innovation and robust decision-making that prioritizes pharmaceutical R&D and consumer health expansion. Her performance is marked by successful portfolio reshaping, including divestment of non-core assets and investing in cutting-edge vaccine and specialty medicine developments. Walmsley's impact has resulted in improved financial stability, enhanced pipeline productivity, and strengthened GSK's position as a leading global healthcare company.
Latest News
**GSK CEO Emma Walmsley to Depart, Succeeded by Luke Miels**
Emma Walmsley, the first woman to lead a major global pharmaceutical company as CEO, will step down from GSK on December 31, 2025, marking the end of a transformative tenure that included the spinoff of Haleon and a strategic pivot to specialty medicines and vaccines. Luke Miels, a seasoned executive with stints at AstraZeneca, Roche, and Sanofi, will take over as CEO on January 1, 2026, tasked with guiding GSK through its next phase amid evolving industry challenges and growth ambitions.
Source: http://www.biopharmadive.com/news/emma-walmsley-retire-gsk-ceo-luke-miels/761344/